Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)
(Cell-based Therapy for Neuropathologies Lab)
Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)
Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)
(Cell-based Therapy for Neuropathologies Lab)
Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)
Creation of a therapeutic drug monitoring (TDM) unit for the optimization of the Dravet syndrome pharmacological therapy
(Laboratory of Bioactive Research and Development (LIDeB))
To create a therapeutic drug monitoring (TDM) unit to carry out the analytical determination in biological fluids of the anticonvulsant drugs used in the treatment of Dravet syndrome.
Creation of a therapeutic drug monitoring (TDM) unit for the optimization of the Dravet syndrome pharmacological therapy
(Laboratory of Bioactive Research and Development (LIDeB))
To create a therapeutic drug monitoring (TDM) unit to carry out the analytical determination in biological fluids of the anticonvulsant drugs used in the treatment of Dravet syndrome.
Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds
(Dravet unit in Biobide)
Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds.
Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds
(Dravet unit in Biobide)
Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds.